The Missing 1.4%: Psychedelics and Older Adults
Description
The Missing 1.4%: Psychedelics and Older Adults
Despite a renaissance in psychedelic research, adults over 65 make up just 1.4% of participants in modern clinical trials, a striking gap given that late-life depression, existential distress at end of life, and neurodegenerative disease are among the conditions for which psychedelic-assisted therapies are most often proposed. This lecture examines what the current evidence actually supports, where it falls silent, and what clinicians and researchers should be asking next.
We'll survey the emerging data across three clinical domains: treatment-resistant depression in older adults, existential distress in palliative care (the most mature evidence base, building on the psilocybin-for-cancer-anxiety trials), and the largely preclinical case for psychedelics in Alzheimer's and dementia, where neuroplasticity and neuroinflammation provide a mechanistic rationale but human data remain anecdotal. Safety considerations specific to ageing populations — cardiovascular reactivity, polypharmacy, fall risk, and cognitive vulnerability, will be discussed alongside encouraging early signals, including phase 1 data on repeated low-dose LSD in healthy older volunteers.
This event is a benefit and all proceeds go to rainforest conservation. - https://www.chuffed.org/project/cloud-forest-los-cedros Tickets on a sliding scale $5 to $100
VOYTEK BEREZA is a transparent, GPhC-licensed, prescribing pharmacist with a specialist focus in neuropsychopharmacology. Below is a brief summary of his experience:
2008 – Master of Pharmacy, University College London (UCL).
2009 – Registered with the General Pharmaceutical Council (GPhC).
2010 – Founded and exited several healthcare ventures.
2014 – Post-grad Prescribing qualification at King’s College London
2015 – Entered ABPI open disclosure register.
2021 – Began research into the Australian psychedelic underground.
2022 – Founded The Transparent Company.
2023 – Contributed to a successful Australian psychedelic rescheduling campaign.
2026 – Appointed Australian Psychedelic Society Sydney Chapter Lead
Voytek believes that the convenience of symptomatic treatment can often prevent individuals from uncovering the true source of their illness. By addressing both exogenous and endogenous factors in a deep holistic manner, we can open the path to conclusive healing.
His current focus is working with patients in the legal psychedelic space. If you would like to book a time to speak to him via Zoom, Google Meet or Signal please book via this link.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity



